Tempest Therapeutics, Inc. Income Statement
TPST|3 years of annual SEC 10-K data (FY2015-FY2017)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Tempest Therapeutics, Inc. reported $277,000 in revenue and $73M in net loss for FY2017. Its profit margin was -26432.9% in FY2017.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2017 | FY2016 | FY2015 |
|---|---|---|---|
| Revenue | $277.0K | $0 | $0 |
| Cost of Revenue | $2.2M | $0 | $0 |
| SG&A Expense | $51.6M | $26.1M | $13.3M |
| R&D Expense | $18.4M | $21.8M | $15.8M |
| Operating Income | -$72.0M | -$47.9M | -$29.1M |
| Income Tax | $75.0K | $0 | $0 |
| Net Income | -$73.2M | -$49.5M | -$29.0M |
| EPS (Diluted) | -$2.70 | -$2.19 | -$1.80 |
| Shares Outstanding | 35.6M | 27.3M | 24.1M |
| Operating Margin | -25992.4% | - | - |
| Profit Margin | -26432.9% | - | - |